BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 18204222)

  • 21. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
    Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
    J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclosporin A inhibits nucleotide excision repair via downregulation of the xeroderma pigmentosum group A and G proteins, which is mediated by calcineurin inhibition.
    Kuschal C; Thoms KM; Boeckmann L; Laspe P; Apel A; Schön MP; Emmert S
    Exp Dermatol; 2011 Oct; 20(10):795-9. PubMed ID: 21707758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between DNA repair gene XPD751 single-nucleotide polymorphisms and prognosis of colorectal cancer.
    Dong Y; Liu JW; Gao YJ; Zhou T; Chen YM
    Genet Mol Res; 2015 May; 14(2):5390-8. PubMed ID: 26125734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
    Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
    Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis.
    Li C; Hu Z; Liu Z; Wang LE; Strom SS; Gershenwald JE; Lee JE; Ross MI; Mansfield PF; Cormier JN; Prieto VG; Duvic M; Grimm EA; Wei Q
    Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2526-32. PubMed ID: 17164380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of XPC, XPD, XPF, and XPG gene polymorphisms on the risk and the outcome of acute myeloid leukemia in a Romanian population.
    Bănescu C; Iancu M; Trifa AP; Dobreanu M; Moldovan VG; Duicu C; Tripon F; Crauciuc A; Skypnyk C; Bogliș A; Lazar E
    Tumour Biol; 2016 Jul; 37(7):9357-66. PubMed ID: 26779634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.
    Park DJ; Zhang W; Stoehlmacher J; Tsao-Wei D; Groshen S; Gil J; Yun J; Sones E; Mallik N; Lenz HJ
    Clin Adv Hematol Oncol; 2003 Mar; 1(3):162-6. PubMed ID: 16224397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients.
    Saldivar JS; Lu KH; Liang D; Gu J; Huang M; Vlastos AT; Follen M; Wu X
    Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S223-9. PubMed ID: 17825393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variants in nucleotide excision repair core genes and susceptibility to recurrence of squamous cell carcinoma of the oropharynx.
    Song X; Sturgis EM; Jin L; Wang Z; Wei Q; Li G
    Int J Cancer; 2013 Aug; 133(3):695-704. PubMed ID: 23335232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
    Huang MY; Tsai HL; Lin CH; Huang CW; Ma CJ; Huang CM; Chai CY; Wang JY
    J Surg Oncol; 2013 Dec; 108(7):457-64. PubMed ID: 23996617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk Modulation of Oral Pre Cancer and Cancer with Polymorphisms in XPD and XPG Genes in North Indian Population.
    Nigam K; Yadav SK; Samadi FM; Bhatt ML; Gupta S; Sanyal S
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2397-2403. PubMed ID: 31450912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single nucleotide polymorphisms and clinical outcome in patients with biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine.
    Pacetti P; Giovannetti E; Mambrini A; Nannizzi S; Orlandi M; Tartarini R; Del Freo A; Del Tacca M; Danesi R; Cantore M
    Anticancer Res; 2009 May; 29(5):1835-40. PubMed ID: 19443413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SNP-SNP interactions between DNA repair genes were associated with breast cancer risk in a Korean population.
    Han W; Kim KY; Yang SJ; Noh DY; Kang D; Kwack K
    Cancer; 2012 Feb; 118(3):594-602. PubMed ID: 21751184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. XPG rs2296147 T>C polymorphism predicted clinical outcome in colorectal cancer.
    Wang F; Zhang SD; Xu HM; Zhu JH; Hua RX; Xue WQ; Li XZ; Wang TM; He J; Jia WH
    Oncotarget; 2016 Mar; 7(10):11724-32. PubMed ID: 26887052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive impact of genetic polymorphisms in DNA repair genes on susceptibility and therapeutic outcomes to colorectal cancer patients.
    Sun K; Gong A; Liang P
    Tumour Biol; 2015 Mar; 36(3):1549-59. PubMed ID: 25355595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.
    Kim JG; Chae YS; Sohn SK; Moon JH; Ryoo HM; Bae SH; Kum Y; Jeon SW; Lim KH; Kang BM; Park IJ; Choi GS; Jun SH
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):953-60. PubMed ID: 19219602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI.
    Seo BG; Kwon HC; Oh SY; Lee S; Kim SG; Kim SH; Han H; Kim HJ
    Oncol Rep; 2009 Jul; 22(1):127-36. PubMed ID: 19513514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer.
    Chen J; Xie F; Chen K; Wang D; Jiang H; Li J; Pan F; Chen S; Zhang Y; Ruan Z; Huang H; Zou L; Liang H
    Cancer Biol Ther; 2009 Jul; 8(14):1424-30. PubMed ID: 19458483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer.
    Gu J; Zhao H; Dinney CP; Zhu Y; Leibovici D; Bermejo CE; Grossman HB; Wu X
    Clin Cancer Res; 2005 Feb; 11(4):1408-15. PubMed ID: 15746040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.